References
1. Freeman M.E., et al. Prolactin: structure, function and regulation of secretion. Physiol Rev. 2000; 80: 1523-631.
2. Patubska S., et al. Hyperprolactinaemia - a problem in patients from the reproductive period to the menopause. Menopause Rev. 2017; 16 (1): 1-7.
3. Melmed S., et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96 (2): 273-88.
4. Soto-Pedre E., et al. Morbidity and mortality in patients with hyperprolac-tinaemia: the PROLEARS study. Endocr Connect. 2017; 6 (8): 580-8.
5. Bernard V., et al. New insights in prolactin: pathological implications. Nat Rev Endocrinol. 2015; 11: 265-75.
6. Melnichenko G.A., et al. Federal clinical guidelines for hyperprolactinemia: clinical picture, diagnosis, differential diagnosis and treatment methods. Moscow, 2015. (in Russian)
7 Mancini T., et al. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am. 2008; 37: 67-9.
8. Vilar L, et al. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J Endocrinol Invest. 2008; 31: 436-44.
9. Bonert V.S., Melmed S. Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenoma. Nat Clin Pract Endocrinol Metab. 2006; 2: 408-12.
10. State register of medicines. Instructions for the use of the medicinal product for medical use «Dostinex». (in Russian)
11. Tollin S.R. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest. 2000; 23: 765-70.
12. Gorobets L.N. Syndrome of neuroleptic hyperprolactinemia: clinical picture, diagnosis, prevention and correction. Manual for doctors. Moscow: Prakticheskaya meditsina, 2014. (in Russian)
13. Verhelst J., et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999; 84: 2518-22.
14. De Rosa M., et al. The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. Clin Endocrinol (Oxf). 2006; 64: 307-13.
15. Ono M. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab. 2008; 93: 4721-7
16. Di Sarno A., et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab. 2001; 86: 5256-61.
17. Biswas M., et al. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf). 2005; 63: 26-31.
18. Kharlip J., et al. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab. 2009; 94: 2428-36.
19. Delgrange E., et al. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol. 2009; 160: 747-52.
20. Christin-Maftre S., et al. Prolactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy. Ann Endocrinol (Paris). 2007; 68: 106-12.
21. Colao A., et al. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxf). 2008; 68: 66-71.
22. Dabbous A., et al. Hyperprolactinaemia in male infertility: clinical case scenarios. Arab J Urol. 2018; 16: 44-52.